

insights

CBD drugs moved to Schedule 5; no promises for cannabis

The DEA has moved CBD prescription drugs with THC levels below .01% to a Schedule 5 drug after the FDA's approval of Epidolex. However, despite the reschedule, cannabis still remains a Schedule 1 substance.

Read the full post, "[CBD drugs moved to Schedule 5; no promises for cannabis](#)," on our [Tracking Cannabis](#) blog.

[authorsTest](#)